Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Aug 4:13:966797.
doi: 10.3389/fphar.2022.966797. eCollection 2022.

Editorial: Women in drug metabolism and transport: 2021

Claudia Bregonzio  1 , Sara Eyal  2 , Franciska Erdő  3 , Mariela Fernanda Pérez  1
Affiliations
Editorial

Editorial: Women in drug metabolism and transport: 2021

Claudia Bregonzio et al. Front Pharmacol. .
No abstract available

Keywords: ADME & toxicity; bioavailability; biosimilar agents; pharmacokinetic; physiologically-based pharmacokinetic.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the ResearchTopic Women in drug metabolism and transport: 2021

References

    1. Grimstein M., Yang Y., Zhang X., Grillo J., Huang S. M., Zineh I., et al. (2019). Physiologically based pharmacokinetic modeling in regulatory science: An update from the U.S. Food and drug administration's office of clinical pharmacology. J. Pharm. Sci. 108 (1), 21–25. 10.1016/j.xphs.2018.10.033 - DOI - PubMed
    1. Huynh C., Brussee J. M., Pouzol L., Fonseca M., Meyer zu Schwabedissen H. E., Dingemanse J., et al. (2021a). Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans. Biomed. Pharmacother. 144, 112363. 10.1016/j.biopha.2021.112363 - DOI - PubMed
    1. Huynh C., Henrich A., Strasser D. S., Boof M. L., Al-Ibrahim M., Meyer zu Schwabedissen H. E., et al. (2021b). A multipurpose first-in-human study with the novel CXCR7 antagonist ACT-1004-1239 using CXCL12 plasma concentrations as target engagement biomarker. Clin. Pharmacol. Ther. 109, 1648–1659. 10.1002/cpt.2154 - DOI - PubMed
    1. Jose V., Singh I., Patel R., Arora S. (2021). Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial. Indian J. Pharmacol. 53 (1), 6–12. 10.4103/ijp.IJP_346_19 - DOI - PMC - PubMed
    1. Muehlan C., Heuberger J., Juif P. E., Croft M., van Gerven J., Dingemanse J., et al. (2018). Accelerated development of the dual orexin receptor antagonist ACT-541468: Integration of a microtracer in a first-in-human study. Clin. Pharmacol. Ther. 104, 1022–1029. 10.1002/cpt.1046 - DOI - PubMed

Publication types

LinkOut - more resources